ReviewCureus2025
Euthyroid Graves' Ophthalmopathy With Negative Antibodies (EGONA): A Comprehensive Case-Based Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Euthyroid Graves' ophthalmopathy with negative antibodies (EGONA) is a rare form of thyroid eye disease. This literature review aims to establish the different presentations seen in the cases of euthyroid Graves' ophthalmopathy with negative antibodies. Despite the thyroid levels being normal, the mechanism by which EGONA causes eye disease is the same as the classical Graves' ophthalmopathy. Proper diagnosis relies mainly on clinical signs and imaging of the eye. A systematic search of PubMed, PubMed Central, and ScienceDirect was conducted with no date restrictions. Articles were included if they were English-language case reports describing patients with euthyroid ophthalmopathy and negative thyroid antibodies during initial presentation, with full-text availability and a documented clinical course. Data from nine articles (12 cases) were extracted, focusing on presentation, management, and outcomes. Treatments include corticosteroids, anti-thyroid medication, and surgery. Prognosis varied between those who developed thyroid imbalances and the presence of antibodies later down the course.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.